About the Authors
- Kendall A Smith
-
*To whom correspondence should be addressed. E-mail: kasmith@med.cornell.edu
Affiliation The Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America
- Sofija Andjelic
-
Current address: Progenics Pharmaceuticals, Tarrytown, New York, United States of America
Affiliation The Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America
- Zoran Popmihajlov
-
Affiliation The Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America
- Liza Kelly-Rossini
-
Current address: Progenics Pharmaceuticals, Tarrytown, New York, United States of America
Affiliation The Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America
- Aquanette Sass
-
Affiliation The Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America
- Martin Lesser
-
Affiliation General Clinical Research Center, Weill Medical College of Cornell University, New York, New York, United States of America
- Steven Benkert
-
Affiliation Investigational Pharmacy, New York Presbyterian Hospital, New York, New York, United States of America
- Cory Waters
-
Affiliation BD Biosciences, San Jose, California, United States of America
- Joyce Ruitenberg
-
Affiliation BD Biosciences, San Jose, California, United States of America
- Paul Bellman
-
Affiliations The Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America, Department of Medicine, Weill Medical College of Cornell University, New York, New York, United States of America
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
KAS, ML, SB, CW, and JR designed the study. KAS, SA, ZP, AS, ML, and CW analyzed the data. KAS, LKR, AS, and PB enrolled patients. SA, ZP, LKR, SB, and CW wrote the paper. SA monitored the immune responses of clinical trial participants. ZP was involved in laboratory evaluations. LKR conducted protocol-specified visits to collect clinical data from study participants and manage adverse events. SB acted as the research pharmacist for this trial, which involved designing the randomization scheme, randomizing patients to treatment, calculating and preparing treatment doses, and blinding the vaccine doses. CW designed experiments and analyzed data associated with the use of the CPLp assay.